The general consensus among physicians is that patients with ulcer should receive surgery or medication but that many physicians do not consult specialists with this condition. Ulcer is treated in many ways.
Ulcer is an inflammation of the mucous membranes of the urogenital and gastrointestinal systems. Common ulcers are found on the lower gastrointestinal tract. Chronic and uncontrolled infections with bacteria or viruses or with parasites are all causes of ulcer pathology.\n
A person's genetic predisposition plays an important role in the onset and development of ulcer in the stomach and esophagus. Tobacco, alcohol and NSAIDs/aspirin use may also increase the risk further. However, the cause of most ulcers remains unknown.\n
The most common symptom of stomach ulcer is chronic stomachache. This symptom is not specific for gastric ulcer, but it is often the first sign of stomach ulcer. It is not possible to rule out gastric irritation with certainty, because the symptoms of irritation can become quite similar with ulcer. Also, if ulcer is not serious, but just very painful or there are some symptoms like nausea, vomiting or dizziness, but the diagnosis is only for a few minutes, gastric irritation can be considered. When there are some other specific signs like pain in extremities, chest pain, sweating, fever or blood in stool, the diagnosis of stomach ulcer is more certain.
According to the 1997 NASE survey, about 1.5 million Americans have an ulcer at some time each year. In this population, rates of major ulcers were about the same as those in Western European countries. Factors that increase the prevalence of an uncomplicated ulcer include age and alcohol consumption. Preventing ulcer is as important as treating it.
Most patients with moderate to severe ulcers could not be cured. Treatment of mild ulcers had a success rate of up to 90%. Better results appear with treatment when the ulceration is asymptomatic.
Ustekinumab treatment is not associated with significant weight gain compared with TNF blockers. Thus, ustekinumab seems to be a promising candidate for obese subjects with active relapsing Crohn's disease. We need to evaluate a larger multicenter study to further explore the efficacy and safety of ustekinumab in obese adults with luminal inflammatory bowel diseases.
Current treatments of ulcer are usually not better than placebo. Nevertheless, new treatment modalities have the potential to offer a significant and reliable breakthrough for patients with ulcer.
Bsa or weight showed a difference in drug induced side effect incidence. Bsa is a better measure to predict for drug effects in a clinical setting when calculating the proper bsa, due to the ease of use and quick response.
The current evidence indicates that ustekinumab improves QoL in chronic Crohn's disease. Dose-based adjustment of ustekinumab for bioavailability improves treatment efficacy while preserving QoL and may be an option in treatment-resistant patients.
In the modern intensive care unit, we see few patients with severe or life-threatening illnesses who are still hospitalized. Ulceration is a common problem and can often be successfully cured.
Children's and their families and parents should be alerted to the significant occurrence of gastric ulcers in families, and that gastric ulcer disease can be prevented.